Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries

Dmitriy Minond, S. Adrian Saldanha, Prem Subramaniam, Michael Spaargaren, Timothy Spicer, Joseph R. Fotsing, Timo Weide, Valery V. Fokin, K. Barry Sharpless, Moreno Galleni, Carine Bebrone, Patricia Lassaux, Peter Hodder

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

VIM-2 is an Ambler class B metallo-β-lactamase (MBL) capable of hydrolyzing a broad-spectrum of β-lactam antibiotics. Although the discovery and development of MBL inhibitors continue to be an area of active research, an array of potent, small molecule inhibitors is yet to be fully characterized for VIM-2. In the presented research, a compound library screening approach was used to identify and characterize VIM-2 inhibitors from a library of pharmacologically active compounds as well as a focused 'click' chemistry library. The four most potent VIM-2 inhibitors resulting from a VIM-2 screen were characterized by kinetic studies in order to determine Ki and mechanism of enzyme inhibition. As a result, two previously described pharmacologic agents, mitoxantrone (1,4-dihydroxy-5,8-bis([2-([2-hydroxyethyl]amino)ethyl]amino)-9,10-anthr acenedione) and 4-chloromercuribenzoic acid (pCMB) were found to be active, the former as a non-competitive inhibitor (Ki =Ki = 1.5 ± 0.2 μM) and the latter as a slowly reversible or irreversible inhibitor. Additionally, two novel sulfonyl-triazole analogs from the click library were identified as potent, competitive VIM-2 inhibitors: N-((4-((but-3-ynyloxy)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzen esulfonamide (1, Ki = 0.41 ± 0.03 μM) and 4-iodo-N-((4-(methoxymethyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfona mide (2, Ki = 1.4 ± 0.10 μM). Mitoxantrone and pCMB were also found to potentiate imipenem efficacy in MIC and synergy assays employing Escherichia coli. Taken together, all four compounds represent useful chemical probes to further investigate mechanisms of VIM-2 inhibition in biochemical and microbiology-based assays.

Original languageEnglish
Pages (from-to)5027-5037
Number of pages11
JournalBioorganic and Medicinal Chemistry
Volume17
Issue number14
DOIs
Publication statusPublished - 15 Jul 2009
Externally publishedYes

Fingerprint

Click Chemistry
Mitoxantrone
Libraries
Assays
Screening
p-Chloromercuribenzoic Acid
Enzyme inhibition
Microbiology
Lactams
Triazoles
Imipenem
Research
Escherichia coli
Anti-Bacterial Agents
Molecules
Kinetics
Enzymes

Keywords

  • β-Lactamase
  • Inhibitors
  • VIM-2

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Minond, D., Saldanha, S. A., Subramaniam, P., Spaargaren, M., Spicer, T., Fotsing, J. R., ... Hodder, P. (2009). Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorganic and Medicinal Chemistry, 17(14), 5027-5037. https://doi.org/10.1016/j.bmc.2009.05.070

Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. / Minond, Dmitriy; Saldanha, S. Adrian; Subramaniam, Prem; Spaargaren, Michael; Spicer, Timothy; Fotsing, Joseph R.; Weide, Timo; Fokin, Valery V.; Sharpless, K. Barry; Galleni, Moreno; Bebrone, Carine; Lassaux, Patricia; Hodder, Peter.

In: Bioorganic and Medicinal Chemistry, Vol. 17, No. 14, 15.07.2009, p. 5027-5037.

Research output: Contribution to journalArticle

Minond, D, Saldanha, SA, Subramaniam, P, Spaargaren, M, Spicer, T, Fotsing, JR, Weide, T, Fokin, VV, Sharpless, KB, Galleni, M, Bebrone, C, Lassaux, P & Hodder, P 2009, 'Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries', Bioorganic and Medicinal Chemistry, vol. 17, no. 14, pp. 5027-5037. https://doi.org/10.1016/j.bmc.2009.05.070
Minond D, Saldanha SA, Subramaniam P, Spaargaren M, Spicer T, Fotsing JR et al. Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorganic and Medicinal Chemistry. 2009 Jul 15;17(14):5027-5037. https://doi.org/10.1016/j.bmc.2009.05.070
Minond, Dmitriy ; Saldanha, S. Adrian ; Subramaniam, Prem ; Spaargaren, Michael ; Spicer, Timothy ; Fotsing, Joseph R. ; Weide, Timo ; Fokin, Valery V. ; Sharpless, K. Barry ; Galleni, Moreno ; Bebrone, Carine ; Lassaux, Patricia ; Hodder, Peter. / Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. In: Bioorganic and Medicinal Chemistry. 2009 ; Vol. 17, No. 14. pp. 5027-5037.
@article{7c20b72fb410482da16eefd4729c1df5,
title = "Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries",
abstract = "VIM-2 is an Ambler class B metallo-β-lactamase (MBL) capable of hydrolyzing a broad-spectrum of β-lactam antibiotics. Although the discovery and development of MBL inhibitors continue to be an area of active research, an array of potent, small molecule inhibitors is yet to be fully characterized for VIM-2. In the presented research, a compound library screening approach was used to identify and characterize VIM-2 inhibitors from a library of pharmacologically active compounds as well as a focused 'click' chemistry library. The four most potent VIM-2 inhibitors resulting from a VIM-2 screen were characterized by kinetic studies in order to determine Ki and mechanism of enzyme inhibition. As a result, two previously described pharmacologic agents, mitoxantrone (1,4-dihydroxy-5,8-bis([2-([2-hydroxyethyl]amino)ethyl]amino)-9,10-anthr acenedione) and 4-chloromercuribenzoic acid (pCMB) were found to be active, the former as a non-competitive inhibitor (Ki =Ki ′ = 1.5 ± 0.2 μM) and the latter as a slowly reversible or irreversible inhibitor. Additionally, two novel sulfonyl-triazole analogs from the click library were identified as potent, competitive VIM-2 inhibitors: N-((4-((but-3-ynyloxy)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzen esulfonamide (1, Ki = 0.41 ± 0.03 μM) and 4-iodo-N-((4-(methoxymethyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfona mide (2, Ki = 1.4 ± 0.10 μM). Mitoxantrone and pCMB were also found to potentiate imipenem efficacy in MIC and synergy assays employing Escherichia coli. Taken together, all four compounds represent useful chemical probes to further investigate mechanisms of VIM-2 inhibition in biochemical and microbiology-based assays.",
keywords = "β-Lactamase, Inhibitors, VIM-2",
author = "Dmitriy Minond and Saldanha, {S. Adrian} and Prem Subramaniam and Michael Spaargaren and Timothy Spicer and Fotsing, {Joseph R.} and Timo Weide and Fokin, {Valery V.} and Sharpless, {K. Barry} and Moreno Galleni and Carine Bebrone and Patricia Lassaux and Peter Hodder",
year = "2009",
month = "7",
day = "15",
doi = "10.1016/j.bmc.2009.05.070",
language = "English",
volume = "17",
pages = "5027--5037",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries

AU - Minond, Dmitriy

AU - Saldanha, S. Adrian

AU - Subramaniam, Prem

AU - Spaargaren, Michael

AU - Spicer, Timothy

AU - Fotsing, Joseph R.

AU - Weide, Timo

AU - Fokin, Valery V.

AU - Sharpless, K. Barry

AU - Galleni, Moreno

AU - Bebrone, Carine

AU - Lassaux, Patricia

AU - Hodder, Peter

PY - 2009/7/15

Y1 - 2009/7/15

N2 - VIM-2 is an Ambler class B metallo-β-lactamase (MBL) capable of hydrolyzing a broad-spectrum of β-lactam antibiotics. Although the discovery and development of MBL inhibitors continue to be an area of active research, an array of potent, small molecule inhibitors is yet to be fully characterized for VIM-2. In the presented research, a compound library screening approach was used to identify and characterize VIM-2 inhibitors from a library of pharmacologically active compounds as well as a focused 'click' chemistry library. The four most potent VIM-2 inhibitors resulting from a VIM-2 screen were characterized by kinetic studies in order to determine Ki and mechanism of enzyme inhibition. As a result, two previously described pharmacologic agents, mitoxantrone (1,4-dihydroxy-5,8-bis([2-([2-hydroxyethyl]amino)ethyl]amino)-9,10-anthr acenedione) and 4-chloromercuribenzoic acid (pCMB) were found to be active, the former as a non-competitive inhibitor (Ki =Ki ′ = 1.5 ± 0.2 μM) and the latter as a slowly reversible or irreversible inhibitor. Additionally, two novel sulfonyl-triazole analogs from the click library were identified as potent, competitive VIM-2 inhibitors: N-((4-((but-3-ynyloxy)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzen esulfonamide (1, Ki = 0.41 ± 0.03 μM) and 4-iodo-N-((4-(methoxymethyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfona mide (2, Ki = 1.4 ± 0.10 μM). Mitoxantrone and pCMB were also found to potentiate imipenem efficacy in MIC and synergy assays employing Escherichia coli. Taken together, all four compounds represent useful chemical probes to further investigate mechanisms of VIM-2 inhibition in biochemical and microbiology-based assays.

AB - VIM-2 is an Ambler class B metallo-β-lactamase (MBL) capable of hydrolyzing a broad-spectrum of β-lactam antibiotics. Although the discovery and development of MBL inhibitors continue to be an area of active research, an array of potent, small molecule inhibitors is yet to be fully characterized for VIM-2. In the presented research, a compound library screening approach was used to identify and characterize VIM-2 inhibitors from a library of pharmacologically active compounds as well as a focused 'click' chemistry library. The four most potent VIM-2 inhibitors resulting from a VIM-2 screen were characterized by kinetic studies in order to determine Ki and mechanism of enzyme inhibition. As a result, two previously described pharmacologic agents, mitoxantrone (1,4-dihydroxy-5,8-bis([2-([2-hydroxyethyl]amino)ethyl]amino)-9,10-anthr acenedione) and 4-chloromercuribenzoic acid (pCMB) were found to be active, the former as a non-competitive inhibitor (Ki =Ki ′ = 1.5 ± 0.2 μM) and the latter as a slowly reversible or irreversible inhibitor. Additionally, two novel sulfonyl-triazole analogs from the click library were identified as potent, competitive VIM-2 inhibitors: N-((4-((but-3-ynyloxy)methyl)-1H-1,2,3-triazol-5-yl)methyl)-4-iodobenzen esulfonamide (1, Ki = 0.41 ± 0.03 μM) and 4-iodo-N-((4-(methoxymethyl)-1H-1,2,3-triazol-5-yl)methyl)benzenesulfona mide (2, Ki = 1.4 ± 0.10 μM). Mitoxantrone and pCMB were also found to potentiate imipenem efficacy in MIC and synergy assays employing Escherichia coli. Taken together, all four compounds represent useful chemical probes to further investigate mechanisms of VIM-2 inhibition in biochemical and microbiology-based assays.

KW - β-Lactamase

KW - Inhibitors

KW - VIM-2

UR - http://www.scopus.com/inward/record.url?scp=67650227781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650227781&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2009.05.070

DO - 10.1016/j.bmc.2009.05.070

M3 - Article

VL - 17

SP - 5027

EP - 5037

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 14

ER -